Foghorn Therapeutics Inc. FHTX R2KPHARMA
Company Overview
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Why Investors Should Care
Generates a return on equity of 68.5%, reflecting efficient use of shareholder capital.
Revenue has grown at a 135.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $30.91M (+36.8% YoY); net profit $-74.28M.
- Trailing 12 Months Year-on-year growth — revenue +112.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 135.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 135.14% |
| 1 Year: | 112.70% |
Stock Price Performance
| 1 Year: | -61.12% |
| 6 Months: | -61.27% |
| 3 Months: | -58.56% |
| 1 Month: | -48.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.74 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 68.5%.
- Compounding revenue at 135.1% over 5 years.
CONS
- Trading 71.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FHTX Foghorn Therapeutics Inc. R2KPHARMA | 2.01 | -2.05 | $119.36M | 0.00% | -62.44% | 68.46% | 135.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 179.00K | 286.00K | 279.00K | 41.00K | 3.92M | 4.49M | 6.63M | 5.31M | 5.60M | 17.48M | 5.05M | 6.89M | 7.81M | 5.95M | 7.56M | 8.15M | 3.27M | 16.07M |
| Operating Income | -13.10M | -13.72M | -15.54M | -18.49M | -23.13M | -23.26M | -26.26M | -27.80M | -29.19M | -28.26M | -33.32M | -32.05M | -17.08M | -28.19M | -26.63M | -23.85M | -22.91M | -21.10M | -18.50M | -21.57M | -8.80M |
| Net Income | -13.09M | -13.95M | -15.72M | -18.37M | -22.99M | -23.11M | -26.08M | -26.91M | -27.31M | -25.77M | -30.49M | -29.49M | -14.35M | -25.02M | -22.98M | -19.12M | -18.83M | -17.94M | -15.85M | -19.88M | -7.19M |
| Diluted EPS | - | - | -2.90 | -3.12 | -0.62 | -0.63 | -0.71 | -0.65 | -0.66 | -0.62 | -0.73 | -0.70 | -0.34 | -0.59 | -0.45 | -0.31 | -0.30 | -0.28 | -0.25 | -0.29 | -0.10 |
| R&D Expense | 11.29M | 11.50M | 13.63M | 16.11M | 18.73M | 18.64M | 20.49M | 24.51M | 25.97M | 26.93M | 29.98M | 29.25M | 26.25M | 25.53M | 23.80M | 24.69M | 21.63M | 21.79M | 20.00M | 18.26M | 18.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 430.00K | 1.32M | 19.23M | 34.16M | 22.60M | 30.91M |
| Operating Income | -51.08M | -68.53M | -100.73M | -117.14M | -107.91M | -102.68M | -86.39M |
| Net Income | -51.13M | -68.80M | -101.32M | -108.88M | -98.43M | -86.62M | -74.28M |
| Diluted EPS | - | -6.23 | -2.73 | -2.62 | -2.34 | -1.58 | -1.18 |
| R&D Expense | 44.36M | 57.72M | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.34M | 255.59M | 519.77M | 404.88M | 285.92M | 283.98M | 198.10M |
| Total Equity | -39.27M | -88.02M | 146.19M | 96.87M | 112.00K | -77.19M | -45.53M | -108.50M |
| Cash & Equivalents | - | 14.98M | 92.80M | 101.14M | 52.21M | 80.34M | 55.45M | 80.88M |
| Long Term Debt | - | 10.96M | 19.65M | 0 | - | - | - | - |
| Total Liabilities | - | 23.81M | 109.41M | 422.90M | 404.77M | 363.11M | 329.51M | 306.60M |
| Current Liabilities | - | 12.65M | 18.85M | 48.69M | 55.20M | 58.44M | 66.99M | 59.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.34M | -31.29M | -50.25M | 193.61M | -118.11M | -100.41M | -86.10M |
| Investing Cash Flow | -964.00K | -108.91M | 36.17M | -244.32M | 144.45M | -29.90M | 112.04M |
| Financing Cash Flow | 23.97M | 217.47M | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Capital Expenditure | -968.00K | -16.18M | -3.31M | -1.21M | -1.22M | -906.00K | -50.00K |
| Free Cash Flow | -47.30M | -47.47M | -53.56M | 192.40M | -119.33M | -101.31M | -86.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | -15,937.4% | -7,637.1% | -609.2% | -315.9% | -454.3% | -279.5% |
| Net Margin % | - | -16,000.0% | -7,681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| ROE % | 58.1% | -47.1% | -104.6% | -97,216.1% | 127.5% | 190.3% | 68.5% |
| ROCE % | -527.2% | -28.9% | -21.4% | -33.5% | -47.4% | -47.3% | -62.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Flagship Pioneering LLC | 21.34% | 12.67M | $25.35M |
| 2 | BVF Inc. | 9.84% | 5.84M | $11.68M |
| 3 | FMR, LLC | 9.61% | 5.71M | $11.41M |
| 4 | Deerfield Management Company, L.P | 7.40% | 4.39M | $8.79M |
| 5 | Blackrock Inc. | 4.42% | 2.63M | $5.25M |
| 6 | Raymond James Financial, Inc. | 4.19% | 2.49M | $4.98M |
| 7 | Euclidean Capital Llc | 2.65% | 1.57M | $3.15M |
| 8 | Vanguard Capital Management LLC | 2.52% | 1.49M | $2.99M |
| 9 | Geode Capital Management, LLC | 1.53% | 910.87K | $1.82M |
| 10 | Siren, L.L.C. | 1.21% | 720.72K | $1.44M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FHTX
Foghorn Therapeutics Inc. (FHTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1LX211Y1B2T2hNNkFzRDE0SUdjbFQxNTNxOUV4QTBvWllEUTExZlZOdDNPeWZrVW9Oa1hzazdlY0trNVNmenFxbnF6ZXhoME9XYWc?oc=5" target="_blank">Foghorn Therapeutics Inc. (FHTX) Stock Price, News, Quot…
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPbGplamlld0pWcDdUQnkxRm0tWXlXM1BibFJEQmtMWTc5ejhTbU9LMnlhSExqOTdIWi1vQjZYa1dYM2o2a3dERE4xTnVKOEdvaFQtdDExdXF0V2tPa0ZpM2RpY2ltbkZJYzN4R1pFX0N3STJRTWhsZW1YV2ZSeU8wRnZCei1fZ01CTlE1OE…
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOVU5FTm1oUUxqMFRHN2J2NHhpSjVBQkM0SHdNMlo1ZE95ajJUUUxnX2x0R3FYUURJR2ZrNHg3blNtU1ppbDg1NHh3MHdxNUxnT1c4aC0tZWhwS2tfNldlR21iLU90LV9OU0hyTVlqMU15VGx0WWE0d2prcklVSjItMnFqQV9ORmRFQmc?oc…
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80% - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPcHhBdHdMZnpXMXFaY0JVdTBmSTBmc2xmN1FmX1AyV2o0bE1YT3pBeExzdGZxSVNkTTgxY3Y4Y0tmMktIS21LNV9XMHpvNE51SHhKRDhPczVoNS1BTm03bGVJRV80LWd0WDBzZVVlTm0wLV8yZ1hXekVNR29icmxqQ1RYejFpUkhZeGg3aU…
Why is Foghorn Therapeutics stock plunging today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxORURpclFsZkpITVVqWTlqTXBtWHdhQ0UtdDEyM0xIQ1ZJb2N4X3VVLVdXekhjOU45RVVBUVVJU24yc1h4UlozRlpFTk1iQkdCeUhVV3lkWndhVV9JSERneTdGLVpLUXhRanZtb3h6TUhnWE1iSHdISWlWSk4xVmJGWU1EYXRnU3gzcy1ZM2…
FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? - TradingView
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOZG8wX0NhVnMtU1hCdGFMeFJjamxuRENDR1k5M3g0RnRDSmFtblZyM3FHOFpxNXRsNExyejJBRVZwT2FqSkFBdFZsd3ZlTkRCOVNpdXhuWDdqZmNoTGZiZ2FkTjYxcHg0czJKc19yRzZSMkNGZmUxV3RoWEYzbnc1dmhOWjJNQXpxT0RBTj…
FHTX — Frequently Asked Questions
What is the current share price of Foghorn Therapeutics Inc. (FHTX)?
As of 2026-10-22 16:30 PDT, Foghorn Therapeutics Inc. (FHTX) trades at $2.01 on NasdaqGM. Its 52-week range is $1.85 to $7.07.
What is the market capitalisation of FHTX?
Foghorn Therapeutics Inc. (FHTX) has a market capitalisation of $119.36M on NasdaqGM.
What is the P/E ratio of FHTX?
FHTX trades at a trailing price-to-earnings (P/E) ratio of -2.05. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is -1.45.
What is the return on equity (ROE) of FHTX?
FHTX has a return on equity (ROE) of 68.46%. Its return on capital employed (ROCE) is -62.44%.
Is FHTX a good stock to buy?
This page provides a data-driven analysis of Foghorn Therapeutics Inc. (FHTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.